Condition: Stroke · Medication Adherence · Sponsor: Northern California Institute of Research and Education
The overall objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II (SMAART-II) is to deploy a hybrid study design to firstly, demonstrate the efficacy of a polypill (Polycap ®) containing fixed doses of antihypertensives, a statin, and antiplatelet therapy taken as two capsules, once daily orally in reducing composite vascular risk over 24 months vs. usual care among 1000 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, SMAART II seeks to develop an implementation strategy for routine integration and policy adoption of this polypill for post-stroke cardiovascular risk reduction in an under-resourced system burdened by suboptimal care and outcomes.
This description comes directly from the study's public registry record.
Bruce Ovbiagele, MD · 415-750-2047 · bruce.ovbiagele@va.gov
Raelle Tagge, MPH · raelle.tagge@ncire.org
Always discuss trial participation with your own doctor first.
| University Teaching Hospital of Parakou | Parakou, Benin | Recruiting |
| Kwame Nkrumah Institute of Science & Technology | Kumasi, Ghana | Active Not Recruiting |
| University of Ilorin Teaching Hospital | Ilorin, Nigeria | Recruiting |
| Aga Khan Hospital | Dar es Salaam, Tanzania | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05963568